Orchestra BioMed Holdings, Inc. approved a 2026 cash bonus plan for executive officers tied to clinical trial and financial objectives, adjusted RSU vesting schedules, and increased base salaries and target bonus percentages for its CEO and President/COO. These changes to executive compensation arrangements are material for investors as they align management incentives with key company milestones.
Key takeaways
The Board approved a 2026 cash bonus plan for all executive officers on February 12, 2026.
Up to 25% of annual bonuses can be paid in Q3 2026 based on mid-year metrics, with up to 75% paid in Q1 2027 based on full-year performance.
The plan includes stretch goals that could result in additional bonuses if achieved.
CEO Mr. Hochman's target bonus percentage increased from 80% to 100% of base salary, and President/COO Mr. Sherman's increased from 80% to 90%.
Base salaries increased by 4% for Mr. Hochman and 10% for Mr. Sherman.
RSU awards will now vest over three years in four equal installments at 18, 24, 30, and 36 months.